identified higher GG than systematic biopsy in 8% (15/192) of men; whereas, systematic biopsy identified higher GG than targeted in 11% (21/192).
INTRODUCTION AND OBJECTIVES:
The PRECISE recommendations for MRI in men on active surveillance (AS) include repeated measurement of each lesion, and attribution of a PRECISE radiological progression score for the likelihood of clinically significant change over time. A 1-5 Likert scale is used where 1 shows regression of a previously visible lesion, 3 denotes stability and 5 is definitive radiological stage progression. We compared the PRECISE score with clinical progression in men who are managed using an MRI-led AS protocol.
METHODS: Men on AS for low or intermediate risk prostate cancer who had had two or more MRI scans between April 2006 and September 2017 were included. A total of 535 scans from 150 men were re-reported by a dedicated radiologist to give a PI-RADS v2 score for each scan, measurement of all lesions and a PRECISE score for the likelihood of radiological progression. Clinical progression was defined by histological progression to ! Gleason Grade Group 3 and/or initiation of active treatment. Tumour growth rate between serial scans was calculated.
RESULTS: Freedom from clinical progression at 12, 24 and 60 months for PRECISE 1-2 was 100% at all time points; for PRECISE 3 it was 98.4%, 96.7%, 96.7% and for PRECISE 4-5 it was 98.5%, 92.4%, 67.1%. There was a significant difference between PRECISE 1-2 vs 4-5 and PRECISE 3 vs 4-5 (p<0.001). Fifty-six men (37%) had a visible lesion on all scans, and their tumour growth rate (%) by planimetry was higher with higher PRECISE scores (p<0.05). Limitations include the fact that serial biopsies were not routinely performed and that the biopsy approach at baseline varied (standard vs targeted).
The Kaplan-Meier curves show the rate of clinical progression stratified by PRECISE score (1-2 vs 3 vs 4-5) in the overall population (n[150).
CONCLUSIONS: Radiological stability (PRECISE 1-3) in men on AS is associated with a high rate of freedom from clinical progression. If men had clinical progression, then this was almost always detectable on MRI. Men with a stable MRI had a very low likelihood of clinical progression and many could avoid routine re-biopsy.
Source of Funding: None

PD50-03 IN THE DECADE OF MRI BASED ACTIVE SURVEILLANCE, WHEN DO BIOPSY UPGRADING RATES STABILIZE?
INTRODUCTION AND OBJECTIVES: Active surveillance(AS) has become a more common management strategy of low and favorable intermediate risk prostate cancers. In the age of MRI targeted biopsy risks of under-staging have declined. However, once a patient pursues active surveillance the likelihood of disease upgrading over time is poorly characterized. We seek to define the risk of upgrading among patients on AS in the MRI era.
METHODS: Men were prospectively enrolled in a trial of active surveillance(AS) with Gleason 3þ3[6 or 3þ4[7 disease diagnosed in the community. Upon entry into the protocol a confirmatory MRI targeted plus systematic 12 core biopsy were performed to confirm the diagnosis of low or favorable intermediate risk prostate cancer. Patients without cancer detected on confirmatory biopsy or patients with high volume disease were considered eligible for active surveillance. Patient demographics, PSA, prostate volume, PIRADs scores, targeted and sextant biopsy yield, and Gleason scores were recorded upon study enrollment and at the time most recent follow up biopsy.
RESULTS: 289 men aged 42-79 years old (mean 62.4) with a mean prostate volume 53.4ml reached eligibility criteria for active surveillance after initial MRI targeted plus systematic biopsy. All patients demonstrated Gleason 3þ3[6 or Gleason 3þ4[7 disease upon study enrollment. Over a mean follow up of 32.6 months (3.2-109.3 months), 35.1% demonstrated Gleason Score upgrading and 14.6% (n[42) of patients were upgraded to 4þ3[7 or higher disease on repeat MRI targeted fusion plus systematic biopsy. On a per year basis, this translated to a 4.8% rate of any upgrading, and a 2.3% rate of upgrading to clinically significant (Gleason Score !4þ3) disease per year. Rates of upstaging appear to level off at approximately 5 years of follow up.
CONCLUSIONS: In the age of MRI targeted biopsy, approximately 5% of patients will undergo upgrading prostate biopsy per year while on active surveillance. Of these upgrading events, 2.3% per year will represent upgrading to clinically significant disease. Additionally, rates of prostate cancer upstaging on prostate biopsy appears to approach zero at approximately 5 years following initial diagnosis. These data
